Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 10 of about 127 citing Mu: Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic.... (0.09 sec) 

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl …


DJ Drucker, MA Nauck - The Lancet, 2006 - Elsevier
Glucagon-like peptide 1 (GLP-1) is a gut-derived incretin hormone that stimulates insulin and
suppresses glucagon secretion, inhibits gastric emptying, and reduces appetite and food
intake. Therapeutic approaches for enhancing incretin action include ...
Cited by 416 - Related articles - All 10 versions

Biology of incretins: GLP-1 and GIP

- rh.dk [PDF] 
LL Baggio, DJ Drucker - Gastroenterology, 2007 - Elsevier
This review focuses on the mechanisms regulating the synthesis, secretion, biological
actions, and therapeutic relevance of the incretin peptides glucose-dependent insulinotropic
polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). The published literature was ...
Cited by 179 - Related articles - All 25 versions

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as …

- januvia.se [PDF] 
I Raz, M Hanefeld, L Xu, C Caria, D Williams-Herman, … - Diabetologia, 2006 - Springer
Abstract Aims/hypothesis The aim of this study was to assess the efficacy and safety of sitagliptin
(MK-0431) as mono- therapy in patients with type 2 diabetes mellitus and inadequate glycaemic
control (HbA 1c Q7% and e10%) on exercise and diet. Methods A total of 521 patients ...
Cited by 167 - Related articles - All 5 versions

{beta}-Cell Failure in Diabetes and Preservation by Clinical Treatment

- endojournals.org
BL Wajchenberg - Endocrine reviews, 2007 - Endocrine Soc
There is a progressive deterioration in ß-cell function and mass in type 2 diabetics. It was found
that islet function was about 50% of normal at the time of diagnosis, and a reduction in ß-cell
mass of about 60% was shown at necropsy. The reduction of ß-cell mass is attributable to ...
Cited by 105 - Related articles - BL Direct - All 7 versions

Dipeptidyl peptidase-4 inhibitors

- diabetesjournals.org
B Ahrén - Diabetes Care, 2007 - Am Diabetes Assoc
The enzyme dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagon-like
peptide-1 (GLP-1). Since GLP-1–based therapy is a promising novel treatment of type 2
diabetes, the strategy to inhibit the enzyme has been explored. Several DPP-4 inhibitors ...
Cited by 51 - Related articles - BL Direct - All 11 versions

Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the …

- dvdres.com [PDF] 
BD Green, PR Flatt, CJ Bailey - Diabetes & Vascular Disease …, 2006 - dvr.sagepub.com
Abstract I nhibitors of the enzyme dipeptidyl peptidase IV (DPP IV) provide a strategy for the treatment
of type 2 dia- betes. DPP IV rapidly inactivates the incretin hor- mones glucagon-like
peptide-1 (GLP-1) and glucose- dependent insulinotropic polypeptide (GIP). Inhibition of ...
Cited by 40 - Related articles - BL Direct - All 9 versions

Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical …

- diabetesjournals.org
DJ Drucker - Diabetes care, 2007 - Am Diabetes Assoc
Dipeptidyl peptidase (DPP)-4 is a complex enzyme that exists as a membrane-anchored cell
surface peptidase that transmits intracellular signals via a short intracellular tail and as a second
smaller soluble form present in the circulation. DPP-4 cleaves a large number of ...
Cited by 42 - Related articles - BL Direct - All 11 versions

The metabolic syndrome and schizophrenia: a review


J Meyer, CE Koro, GJ … - International Review of …, 2005 - informahealthcare.com
Summary The clinical phenomenon described as the metabolic syndrome has received considerable
attention both in the recent medical literature and popular press. Many of the sequelae of events
attributable to newer atypical antipsychotics are consistent with the metabolic syndrome ...
Cited by 34 - Related articles - All 8 versions

Inhibition of GSK3 promotes replication and survival of pancreatic beta cells


R Mussmann, M Geese, F Harder, S Kegel, U … - Journal of Biological …, 2007 - ASBMB
Recent developments indicate that the regeneration of beta cell function and mass in patients
with diabetes is possible. A regenerative approach may represent an alternative treatment option
relative to current diabetes therapies that fail to provide optimal glycemic control. Here we ...
Cited by 30 - Related articles - All 7 versions

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on …


GA Herman, PP Stein, NA Thornberry, JA … - Clinical Pharmacology & …, 2007 - nature.com
Dipeptidyl peptidase-4 (DPP-4) inhibitors represent a new class of oral antihyperglycemic agents
to treat patients with type 2 diabetes. 1 DPP-4 inhibitors improve fasting and postprandial glycemic
control without hypoglycemia or weight gain. 1 This article focuses on the physiology, ...
Cited by 29 - Related articles - All 4 versions


Result Page: 

1

2

3

4

5

6

7

8

9

10

Next


 


Go to Google Home - About Google - About Google Scholar

©2009 Google